A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

NCT05038020 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to safety findings in other AKST4290 studies

Conditions

Diabetic Retinopathy

Interventions

DRUG: AKST4290
DRUG: Placebo

Sponsor

Alkahest, Inc.